| 10.72 -0.13 (-1.2%) | 10-24 15:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 17.72 | 1-year : | 20.95 |
| Resists | First : | 15.17 | Second : | 17.94 |
| Pivot price | 14.05 |
|||
| Supports | First : | 10.71 | Second : | 8.91 |
| MAs | MA(5) : | 11.37 |
MA(20) : | 14.19 |
| MA(100) : | 12.01 |
MA(250) : | 0 | |
| MACD | MACD : | -0.3 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 2.2 |
D(3) : | 3.1 |
| RSI | RSI(14): 35.1 |
|||
| 52-week | High : | 19.57 | Low : | 4.88 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AARD ] has closed above bottom band by 15.2%. Bollinger Bands are 100.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 11.35 - 11.46 | 11.46 - 11.53 |
| Low: | 10.58 - 10.72 | 10.72 - 10.81 |
| Close: | 10.69 - 10.92 | 10.92 - 11.05 |
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation. It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.
Mon, 06 Oct 2025
Insiders Rewarded With US$275k Addition To Investment As Aardvark Therapeutics Stock Hits US$349m - simplywall.st
Thu, 02 Oct 2025
Aardvark Therapeutics (NASDAQ:AARD) Now Covered by Jones Trading - Defense World
Tue, 16 Sep 2025
Aardvark therapeutics CEO Lee Tien-Li buys $96,623 in shares - Investing.com
Fri, 12 Sep 2025
Aardvark therapeutics CEO Lee Tien-Li buys $160k in AARD - Investing.com
Thu, 14 Aug 2025
Aardvark Therapeutics, Inc.'s (NASDAQ:AARD) stock price dropped 11% last week; individual investors would not be happy - simplywall.st
Mon, 03 Mar 2025
Aardvark Therapeutics (AARD): Among Stocks With At Least $10 Million In Insider Spending Recently - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 22 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 14.5 (%) |
| Held by Institutions | 50.6 (%) |
| Shares Short | 586 (K) |
| Shares Short P.Month | 666 (K) |
| EPS | -1.7 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.3 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -21.8 % |
| Return on Equity (ttm) | -33.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.89 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -33 (M) |
| Levered Free Cash Flow | -19 (M) |
| PE Ratio | -6.39 |
| PEG Ratio | 0 |
| Price to Book value | 1.71 |
| Price to Sales | 0 |
| Price to Cash Flow | -7.12 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|